CO2 Solutions Inc. announced unaudited consolidated financial results for the third quarter and nine months ended March 31, 2017. The Corporation recorded revenues for the three-month period and the nine-month period ended March 31, 2017 of $0.05 million related to the sale of carbonic anhydrase enzyme to a third party for use in CO2 capture for enhancing the growth of algae for economical, sustainable production of protein and biofuel products. The Corporation recorded a loss of $0.90 million or $0.01 per share, for the three-month period ended March 31, 2017, an increase of $0.25 million from the loss of $0.66 million, or $0.00 per share, for the same period in 2016. For the nine-month period ended March 31, 2017, the Corporation recorded a loss of $3.65 million or $0.03 per share, a small increase of $0.02 million from the loss of $3.64 million, or $0.03 per share, for the same period in 2016.